Cancer Cell:端粒损伤介导四倍体形成促发癌变

2012-06-17 bo 生物谷

6月12日,Cancer Cell杂志报道了关于端粒失调与异常核型细胞产生及肿瘤发生之间关系的最新研究。 人类亚四倍体核型肿瘤细胞被认为起源于四倍体前体细胞,但形成四倍体的起因尚不明了。此前,有研究证实,小鼠细胞核内复制伴有持续的端粒功能失调和全基因组范围的DNA损伤。 本研究发现,在人类成纤维细胞和乳房上皮细胞端粒危机时,伴有核内复制和有丝分裂失调。研究者还发现p53和Rb可抑制四倍体形成。

6月12日,Cancer Cell杂志报道了关于端粒失调与异常核型细胞产生及肿瘤发生之间关系的最新研究。

人类亚四倍体核型肿瘤细胞被认为起源于四倍体前体细胞,但形成四倍体的起因尚不明了。此前,有研究证实,小鼠细胞核内复制伴有持续的端粒功能失调和全基因组范围的DNA损伤。

本研究发现,在人类成纤维细胞和乳房上皮细胞端粒危机时,伴有核内复制和有丝分裂失调。研究者还发现p53和Rb可抑制四倍体形成。利用可诱导系统造成短期端粒破坏,研究者发现端粒驱动的四倍体形成加强了小鼠细胞的癌性转化。遗传导致的肿瘤,类似于人类实体瘤,演变出亚四倍体核型。这些数据证实,特别短的端粒诱导了端粒驱动的四倍体形成。这在癌性损伤早期具有促进肿瘤发生的潜能。(生物谷bioon.com)

 

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Telomere-Driven Tetraploidization Occurs in Human Cells Undergoing Crisis and Promotes Transformation of Mouse Cells

Teresa Davoli, Titia de Lange

Human cancers with a subtetraploid karyotype are thought to originate from tetraploid precursors, but the cause of tetraploidization is unknown. We previously documented endoreduplication in mouse cells with persistent telomere dysfunction or genome-wide DNA damage. We now report that endoreduplication and mitotic failure occur during telomere crisis in human fibroblasts and mammary epithelial cells and document the role of p53 and Rb in repressing tetraploidization. Using an inducible system to generate transient telomere damage, we show that telomere-driven tetraploidization enhances the tumorigenic transformation of mouse cells. Similar to human solid cancers, the resulting tumors evolved subtetraploid karyotypes. These data establish that telomere-driven tetraploidization is induced by critically short telomeres and has the potential to promote tumorigenesis in early cancerous lesions.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868523, encodeId=67e51868523e5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 20 06:03:00 CST 2012, time=2012-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958755, encodeId=13a91958e5585, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 15 13:03:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396702, encodeId=34811396e0295, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557014, encodeId=2020155e0141a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868523, encodeId=67e51868523e5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 20 06:03:00 CST 2012, time=2012-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958755, encodeId=13a91958e5585, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 15 13:03:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396702, encodeId=34811396e0295, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557014, encodeId=2020155e0141a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-11-15 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868523, encodeId=67e51868523e5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 20 06:03:00 CST 2012, time=2012-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958755, encodeId=13a91958e5585, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 15 13:03:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396702, encodeId=34811396e0295, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557014, encodeId=2020155e0141a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868523, encodeId=67e51868523e5, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Aug 20 06:03:00 CST 2012, time=2012-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958755, encodeId=13a91958e5585, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 15 13:03:00 CST 2012, time=2012-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396702, encodeId=34811396e0295, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557014, encodeId=2020155e0141a, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Tue Jun 19 11:03:00 CST 2012, time=2012-06-19, status=1, ipAttribution=)]
    2012-06-19 axin014

相关资讯

Neoplasia:陈吉龙等免疫细胞癌变的信号通路研究中获新进展

免疫细胞癌变可导致各种白血病/淋巴癌的发生,这些是人类常见的恶性肿瘤。淋巴细胞和粒细胞等由于某些特殊原因发生变异而诱发细胞癌变,其中Bcr-Abl融合癌基因主要诱发了慢性粒细胞白血病(CML)和急性淋巴细胞白血病(ALL)。Bcr-Abl癌蛋白介导细胞癌变的过程涉及多种信号转导通路的分子调控,其中JAK/STAT是关键信号通路之一。SOCS家族蛋白作为细胞因子信号通路的抑制因子,能有效地调节JAK

Cancer Res.:肿瘤缺氧途径研究新模型

6月4日Cancer Research杂志在线报道了一种新开发的缺氧感受信号通路斑马鱼体内研究系统,为深入研究缺氧在肿瘤中作用提供了有力的新手段。 缺氧信号通路是肿瘤细胞病理过程的核心调控者。过去对氧浓度感受途径的关键因子von Hippel-Lindau肿瘤抑制蛋白(pVHL)以及HIF转录因子虽然研究得很多,但是还需要加强在生物模型中对缺氧途径的研究,以加深人类对肿瘤病理的理解,促进新治疗手

Mol Cancer Res:YAP1蛋白触发脑膜瘤细胞增殖

近日,约翰霍普金斯大学的研究人员发表论文称:他们已经发现脑膜瘤生长的重要的细胞机制之一。 在脑膜瘤细胞中,Baia研究激活的蛋白质YAP1,这是由Hippo调控的蛋白。没有Hippo,YAP1会移动到细胞核,并激活触发肿瘤细胞增殖的基因。 近年来,已发现Hippo信号通路在其他类型的癌细胞生长中发挥了作用,但该研究是第一次证实该通路与脑膜瘤有关。YAP1也与其他癌症有关联包括肺癌和卵巢的恶性肿

Nature:AMPK酶在癌症中的双重作用

近日,伊利诺伊州芝加哥大学医学院研究人员发现一个既能抑制细胞增殖,同时又能帮助肿瘤起始阶段的肿瘤细胞以及肿瘤细胞转移至其他器官阶段中细胞存活的蛋白分子。这项研究结果发表在5月31日的Nature杂志上。 这项新的研究结果似乎违背先前的研究结论,这项新研究发现AMP活化的蛋白激酶或AMPK的激活酶能抑制肿瘤细胞的生长。 生物化学和分子遗传学教授Nissim Hay表示:由于其在抑制癌细胞

Nat Struct Mol Biol:内含子RNA调节EZH2表观遗传调控

6月3日,Nature Structural & Molecular Biology杂志报道了内含子RNA调节组蛋白赖氨酸N端甲基转移酶EZH2表观遗传调控的最新进展。 在基因组许多位点的表观遗传修饰异常是肿瘤的一个重要特征。有观点认为,某些RNA分子可指导抑制性多梳蛋白复合物(PRC2)到达特定的染色质区域。 研究者利用体内交叉连接手段在肿瘤细胞中检测和确定PRC2-RNA直接相互作

PNAS:揭示肿瘤细胞在空间受限环境中快速迁移的机制

在一项研究中,美国州大学伯克利分校生物工程教授Sanjay Kumar实验室发现肿瘤细胞在体内有限空间中能够迁移得更快。2012年6月11日,这篇研究论文在线发表在PNAS期刊上,共同作者为Sanjay Kumar和博士后研究员Amit Pathak。 科学家们知道,肿瘤对组织的浸润受到组织机械性能如硬度和组织微观结构特性如孔径大小的调节。但是,过去试图详细地研究和理解这些机制的努力一直受到限制